ArticleEpidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil2024
Hormone use among the transgender, transvestites and non-binary population of Porto Alegre, Brazil, 2021: a cross-sectional study.
Article in Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the prevalence of hormone use, sociodemographic profile, and access to health services among the transgender, transvestite, and nonbinary population in Porto Alegre, capital city of Rio Grande do Sul state.
methodsA cross-sectional study was conducted between September and November 2021, using a snowball sampling method (n=65). Data were collected through a self-administered questionnaire with transgender people aged 18 years or older.
resultsHigh hormone use was observed (n=47), with a higher occurrence of self-medication among transgender women, transvestites, and transfeminine people (n=10). Health monitoring predominantly occurs in gender identity outpatient clinics (n=56). Episodes of transphobia when accessing health services were reported by 28 individuals.
conclusionThis study demonstrated high prevalence of hormone use, highlighted specific patterns of use across different gender identities, and the need for improvements in access to healthcare services. MAIN
resultsHigh prevalence of hormone use was observed (n=47), with emphasis on formulations containing estrogen (n=12) or testosterone cypionate (n=22). Self-administered hormone therapy was higher among transgender women, transvestites and transfeminine people (n=10). IMPLICATIONS FOR SERVICES: This study contributes to understanding the process of self-administered hormone therapy and the need for appropriate interventions. It highlights the importance of establishing strategies that ensure access without discrimination based on gender identity. PERSPECTIVES: Further studies are needed on this topic to encourage the inclusion of medications used in hormone therapy in the National List of Essential Medicines, with the aim of making access to hormones more equitable and universal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.